I am back from JPM and it was a busy couple of days. I need organize my thoughts and today was not a great day given that it is start of the semester. So I will keep this short and sweet with some broad comments and thoughts. Obviously the sector is doing well, which is […]
January 10 Biotech Update- The Revenge of Momentum
Another busy day in the market. It seems like the small caps want to steal the show and perhaps we will see the large caps take the next leg higher with their presentations next week. I have been saying for awhile that JPM would be a tell for the sector and while the conference has […]
Jan 8 Biotech Update- Looking to Europe for Value and Some Deals at Home
Well, it seemed like yesterday was the day of good data and today was the day of buyouts, what will tomorrow bring? The day of partnerships or the calm before the storm or something completely different? Regardless, two days of good news in the sector gave us a strong morning move that held up well […]
January 7 Biotech Update: Good News for PCYC, EPZM, and FMI
I thought yesterday was going to start a run in biotechs but I was a day early. We had the broad market rally helping but the sector was pushed today by some positive news. Of course, every move higher in the sector is bemoaned as being too much making this one of the most hated […]
January 6 Biotech Update: A Slow Start to the Year
I hope everyone had a great holiday and is ready for 2014. It has not been a stellar start for the market or biotechs, which is a little worrisome but it is still early. I have been arguing that the best tell for biotechs will be the price action from the JPM healthcare conference. I […]
December 20 Biotech Update- Wrapping up the Year
It was a good day for the market and biotechs were strong once again. It seems like tax loss selling is winding down and selling volume is starting to dry up. So we are likely to have a positive bias for the rest of the year. It also helps that the news flow in biotechs […]
December 12 Daily Biotech Update- More Thoughts from ASH
Today was a better day for biotechs but I still think that many of them want to test their moving averages which are still lower than these levels. As such, I am cautious about adding at this point but I am certainly not selling either. I am going to continue with my impressions from ASH […]
December 5 Biotech Update- Who is Bayes and what does he have to do with Biotech?
Another slow day in the market but this will clearly change as we enter into ASH this weekend and early next week. At least we should have some interesting data to talk about. We were starting to see some ASH names move today, which is to be expected given we are days away from critical […]
December 3 Biotech Update- CELG partnering and some interesting price action
The market sold off and took a number of biotechs with it, although there were some that bucked the trend. I would not read anything into the selling today as it seemed more like a breather and macro related than something specific to biotech. In fact, it seemed much more akin to a buyer strike […]
December 2 Biotech Update- Getting Ready for ASH
Last week ended well for biotechs and today was a little more of the same with perhaps some consolidation. News has been relatively limited as most traders/investors/general biotech followers are gearing up for ASH. I will be heading down on Friday and staying through Tuesday, which means there will not be any updates this Friday, […]
November 18-EOD
Thankfully there was not a lot of news but biotechs did not just drift lower. I still worry about tax loss selling hitting the sector (or at least the small to mid caps) heading into the end of the year but it is nice to see that the sector can tread water on no news […]
November 13-EOD
It is difficult to get a real sense of where the sector is going outside of down. Obviously one could draw the conclusion that sentiment is negative (and it is) but I am seeing more pockets of strength than the other days. What is difficult is that there does not really seem to be a […]
ASH 2013 Preview on Lymphoid Malignancies
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking the biotech sector’s run the past 2 years. They are now within months of receiving approval for 2 indications where they could benefit patient lives […]
November 4- EOD
(This was from yesterday. Due to the server issues, I am not sure many of you saw it, so I am reposting.) I take one day to not write an EOD and biotechs sell off. Well, they have been weak for awhile so no real surprise but at least the selling does not seemed related […]
ASH 2013 Preview on Multiple Myeloma
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs on the backs of Pharmacyclic’s Ibrutinib (stock is up 1000% since ASH11), Celgene’s Revlimid (~67% of their $6.3B 2013 revenue) and Amgen’s $10.6B deal for […]
October 31- EOD
ARIA is doing its best to single handedly crush biotech sentiment and grind it into a bloody pulp. As I have said before, if this is the bursting of a real speculative bubble then we have another five to ten years of selling (I think it took tulip prices over a century to recover and […]
October 24-EOD
I want to be cautiously optimistic on the recent performance of biotechs. Yesterday ending up being a decent day and today started off okay. The sector is not burning it up with outperformance but seems to taking a pause in the selling. I have been warning that this is a busy week and it continues […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
September 6- EOD
The week ended with some interesting action and volatility over Syria news. The markets appear jumpy but note that the sell off was over the words of Putin. I think a limited American led strike is basically accepted and priced in but the key will be the response. If Syria (and Russia/Iran) accept it and […]
